Back to top
more

Blueprint Medicines (BPMC)

(Real Time Quote from BATS)

$85.20 USD

85.20
60,658

-0.80 (-0.93%)

Updated Oct 18, 2024 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.

Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer

by Zacks Equity Research

The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.

Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

Blueprint Medicines (BPMC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 71.96% and 31.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.

Blueprint Medicines Up on Positive Top-Line Data From SM Study

by Zacks Equity Research

Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares up.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Company News for Sep 23, 2020

by Zacks Equity Research

Companies in the news are: NEOG, TSLA, BPMC, BLNK

Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC

by Zacks Equity Research

Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.

Why Is Blueprint Medicines (BPMC) Up 0.1% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

by Zacks Equity Research

Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines, Roche to Develop Pralsetinib for Cancer

by Zacks Equity Research

Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

by Zacks Equity Research

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.

Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist

by Zacks Equity Research

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

All You Need to Know About Blueprint Medicines (BPMC) Rating Upgrade to Buy

by Zacks Equity Research

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

How Blueprint Medicines (BPMC) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y

by Zacks Equity Research

Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 1.86% and 27.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

by Zacks Equity Research

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Menlo (MNLO) in Focus: Stock Moves 9.9% Higher

by Zacks Equity Research

Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis

by Zacks Equity Research

The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Blueprint Medicines (BPMC) Upgraded to Buy: Here's Why

by Zacks Equity Research

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.